文献速递白血病

Ropeginterferon alfa-2b对比监测在CML停用TKI后随机3期试验

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
PubMed 文献 · Leukemia · 2026-01-12

ENDURE/CML-IX是一项随机3期试验,纳入203例TKI停药后稳定深度分子学缓解的CML患者,1:1接受ropeg-IFN(100 µg皮下每两周一次,15个月,n=95)或单纯观察(n=108)。中位随访36个月,25个月无分子学复发生存率ropeg-IFN组56%、观察组59%(HR 1.02,95%CI 0.68-1.55,P=0.91)。ropeg-IFN维持治疗未改善TKI停药后持续无治疗缓解的概率。

要点

  • TKI停药后加用ropeg-IFN未提高25个月无分子学复发生存率。
  • ropeg-IFN组与观察组25个月MRFS分别为56%和59%,差异无统计学意义。
  • TKI重启后83例有分子学数据者中79例(95%)至少恢复MMR,78例在12个月内恢复。

核心结论

  • 在稳定深度分子学缓解的CML患者中,TKI停药后使用ropeg-IFN维持治疗未改善持续无治疗缓解的概率。

研究设计与样本

  • 随机3期ENDURE/CML-IX试验(NCT03117816;EUDRA-CT 2016-001030-94),203例TKI停药后稳定深度分子学缓解的CML患者按1:1随机接受ropeg-IFN(100 µg皮下每两周一次,15个月,n=95)或单纯观察(n=108)。

主要发现

  • 中位随访36个月,25个月无分子学复发生存率ropeg-IFN组为56%(95%CI 45-66),观察组为59%(95%CI 49-68),HR 1.02(95%CI 0.68-1.55),P=0.91。
  • 83例TKI重启后有分子学数据的患者中,79例(95%)至少恢复MMR,其中78例在12个月内恢复(中位3个月,四分位距2-4个月)。
  • ropeg-IFN耐受性良好,中位给药剂量92 µg(范围3-104),未观察到新的安全性信号。

临床怎么用

  • 对于TKI停药后稳定深度分子学缓解的CML患者,不推荐常规加用ropeg-IFN来维持无治疗缓解。
  • TKI停药后需监测分子学复发,重启TKI后多数患者可在12个月内恢复MMR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-free remission (TFR) after discontinuation of ABL tyrosine kinase inhibitors (TKIs) is an important therapeutic goal in chronic myeloid leukemia (CML). Interferon-α (IFN) has been suggested to promote durable TFR. The phase 3 ENDURE trial (NCT03117816; EUDRA-CT 2016-001030-94) prospectively tested this hypothesis in patients with stable deep molecular remission after TKI therapy. A total of 203 patients were randomised 1:1 to receive ropeginterferon alfa-2b (ropeg-IFN; 100 µg subcutaneously every two weeks for 15 months, n = 95) or observation alone (n = 108) after TKI discontinuation. The primary endpoint was molecular relapse-free survival (MRFS), defined as time to loss of major molecular response (MMR) or death. At a median follow-up of 36 months, 25-month MRFS was 56% (95% confidence interval (CI), 45-66) with ropeg-IFN and 59% (95% CI, 49-68) with observation (hazard ratio (HR), 1.02; 95% CI, 0.68-1.55; P = 0.91). Among 83 patients with molecular data after TKI restart, 79 (95%) regained at least MMR, 78 within 12 months (median 3 months, interquartile range: 2-4 months). Ropeg-IFN was well tolerated (median administered dose of 92 µg, range 3-104), and no new safety signals were observed. Ropeg-IFN maintenance did not improve the probability of sustained TFR after TKI discontinuation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Burchert A, Nicolini FE, le Coutre P, et al. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia. 2026. PMID: 41526617. doi:10.1038/s41375-025-02859-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。